key: cord-0842357-98ejxivc
authors: Oliveira, Carlos R.; Niccolai, Linda M.; Sheikha, Hassan; Elmansy, Lina; Kalinich, Chaney C.; Grubaugh, Nathan D.; Shapiro, Eugene D.
title: Assessment of Clinical Effectiveness of BNT162b2 COVID-19 Vaccine in US Adolescents
date: 2022-03-03
journal: JAMA Netw Open
DOI: 10.1001/jamanetworkopen.2022.0935
sha: 774b6212d6f45755f0a63082b749f7bac496031d
doc_id: 842357
cord_uid: 98ejxivc

IMPORTANCE: The emergence of the B.1.617.2 (Delta) variant of SARS-CoV-2 has led to increases in both infections and hospitalizations among adolescents. Little is known about the effectiveness of the BNT162b2 vaccine in adolescents in the general population, as opposed to a clinical trial population. OBJECTIVE: To estimate the effectiveness of the BNT162b2 vaccine in adolescents aged 12 to 18 years. DESIGN, SETTING, AND PARTICIPANTS: This was a matched case-control study among adolescents (aged 12-18 years) who had results from a SARS-CoV-2 reverse transcription–polymerase chain reaction (RT-PCR) test. Immunization histories, relevant clinical data, and RT-PCR test results were obtained from the Yale New Haven Health System’s medical records between June 1, 2021, and August 15, 2021, when the Delta variant caused 92% of infections in Connecticut. Case participants were defined as adolescents who had a positive test result and an associated medical encounter. Control participants were defined as those who had a negative test result and were matched to a case participant by age, county of residence, and date of testing. EXPOSURES: Adolescents were defined as fully immunized if they had received 2 doses of vaccine at least 14 days before focal time. MAIN OUTCOMES AND MEASURES: The primary outcome measured was SARS-CoV-2 infection confirmed by RT-PCR. The vaccine’s effectiveness (VE) was estimated using matched odds ratios from conditional logistic regression models. Secondary measures included estimated VE by clinical symptoms, number of vaccine doses received, and elapsed time from immunization. RESULTS: A total of 6901 adolescents were tested for SARS-CoV-2. The final sample comprised 186 case participants and 356 matched control participants. The median age was 14 (IQR, 13-16) years, 262 (48%) identified as female, 81 (15%) as Black, 82 (15%) as Hispanic, and 297 (55%) as White. Overall, 134 (25%) were fully immunized (case participants, 10 [5%]; control participants, 124 [35%]). The median time between immunization and the SARS-CoV-2 test was 62 days (range, 17-129 days). Within 4 months of receiving 2 doses, VE against any infection was estimated to be 91% (95% CI, 80%-96%); against asymptomatic infection, 85% (95% CI, 57%-95%). Effectiveness after a single dose was estimated to be 74% (95% CI, 18%-92%). CONCLUSIONS AND RELEVANCE: In this retrospective case-control study of US adolescents, 2 doses of BNT162b2 vaccine appeared to provide excellent protection for at least 4 months after immunization against both symptomatic and asymptomatic SARS-CoV-2 infections.

This supplemental material has been provided by the authors to give readers additional information about their work. 

Using established formulas, we calculated sample sizes for different proportions of controls that might be vaccinated and for a 1:1, 2:1, and 3:1 ratio of controls to cases. 1, 2 The number of cases needed to detect a range of estimates of the vaccine's effectiveness with α < 0.05 and a power of 80-90% are presented below.

Though it was not known what the vaccine uptake would be in this subgroup of the population, a priori, we extrapolated from the national surveys that found approximately a third of adolescents <18 years of age were fully immunized as of July 2021. 3 Assuming that >30% of controls would be fully immunized, our study, with 186 casecontrol sets (2:1 ratio), was powered (≥ 90%) to detect a minimal effectiveness of 50% (two-tailed alpha < 0.05). 

Unadjusted and adjusted odds ratios (OR), along with their 95% confidence intervals (CI), were estimated using conditional logistic regression. The vaccine's effectiveness (VE) was calculated as (1 − OR) x 100%. The log odds of SARS-CoV-2 infection for individuals in matched sets was modeled using the following conditional logistic model:

where αi is the stratum-specific constant term for each matched set, βe is the coefficient denoting immunization status, and β1 through βk are the coefficients for each potential confounder included in the model. For the primary analysis, the immunization status was coded as '1' if the patient received two doses of SARS-CoV-2 vaccine 14 days before focal time and as '0' otherwise (including unvaccinated). Our modeling strategy was to create models that always contain the immunization status and additional potential confounders as needed. Missing data were reported or included within a level of a categorical variable (i.e., unknown race/ethnicity).

To assess for variation in the VE by the number of doses received, we created a categorical variable coded as '1' if the patient received only one dose, '2' if they received two doses, and '0' otherwise (including unvaccinated). Exponentiating the beta coefficient for the different levels of categorical vaccine variable yields the OR for those given one or two doses compared with unvaccinated. To test if there are significant differences between one and two doses (i.e., pair-wise comparisons), we recoded the categorical vaccine variable using two doses as the referent category and interpreted the corresponding beta coefficients, as previously described. 4, 5 To assess the effect of time since immunization on the effectiveness of the vaccine, four new terms were created to account for time in 4-week intervals (i.e., 1-4 weeks, 5-8 weeks, 9-12 weeks, and 13-17 weeks prior to focal time). These terms equaled to 1 for patients who were immunized a given number of weeks prior to focal time (e.g., 1-4 weeks) and 0 for everybody else, including all unvaccinated patients.

To address model-selection uncertainty, we compared the adjusted VE (aVE) and the vaccine coefficient's error terms (on the logit scale) using different model-selection approaches: the full model, the two-stage selection, stepwise backward elimination (using p-value), change-in-estimate method, and standardized mean difference method (SMD). The full model adjusted for nine potential confounders: age, sex, race/ethnicity, health insurance, at least one comorbidity, obesity, the month of the year sample was obtained, the number of medical visits after 1/1/20, and recent exposure to Covid-19. After fitting the full model, we first tested the two-stage approach. In the two-stage method, each of the potential confounders was considered separately using conditional logistic regression models, and a multivariable model was built by including all statistically significant variables using a p-value <0.05 as the cutoff. 6 Three variables (age, race/ethnicity, and insurance status) were selected using this approach. The results of the two-stage selection approach are shown below.

The backward elimination began with the "full model" (all potential confounders), and then each potential confounder was eliminated, one at a time (least significant first), based on whether it had a p-value cutoff of <0.05 7 . Two variables were selected (age and insurance status) using the backward elimination approach. For the change-inestimate approach, potential confounders were selected in a stepwise fashion, and variables were eliminated using a backward strategy if its inclusion caused a change in the VE measurement of <5%. 8 Using the change-in-estimate approach, only the variable for age was maintained in the multivariate model. For the SMD approach, multivariable models were built similar to the 2-stage method; however, an SMD >0.2 was used as the cutoff (rather than pvalue). 9 Using this approach led to the inclusion of variables for race/ethnicity, insurance status, and SARS-CoV-2 exposure. The adjusted OR and standard errors were similar regardless of the model selection approach that was used (eFigure 3). P values for odds ratio (OR) estimated using conditional logistic regression. All estimates include the variable denoting immunization status.

a Race or ethnic group was determined from electronic health records. Other race included Asian, American Indian or Alaska native, native Hawaiian, pacific islander, and mixed race.

b Any comorbidities, see Table 2 for more details c The BMI denotes body-mass index is the weight in kilograms divided by the square of the height in meters

Even after matching and adjusting for potential confounders, residual selection bias can be seen if unmeasured or unidentified factors are associated with the subject's propensity to be immunized or propensity to seek medical care and the selection mechanism in the study. To assess for the potential of residual selection bias, we incorporated measurements of a "sham" exposure (i.e., a vaccine that does not affect the outcome of interest but has a similar likelihood of being received at about the same time as the vaccine of interest) into the design of this study and compared the proportion of cases and the proportion of matched controls who received the sham exposure before focal time. 10 Since influenza vaccines are recommended to be given to all adolescents but have no effect on the risk of developing SARS-CoV-2 infection, we expected that in the absence of residual selection bias, there would be no significant difference in the proportions who had received the vaccine.

The logic behind using a sham exposure is shown in the casual diagram below. From this diagram, we can see that if the apparent effectiveness of the vaccine is due to selection bias from an unmeasured factor related to immunization, then the sham exposure may also erroneously appear to be effective at preventing disease (i.e., SARS-CoV-2 infection in this study). On the other hand, if the proportions of cases and of matched controls that had received >1 dose of the sham vaccine (i.e., influenza vaccine in this study) were similar but there is still a significant difference in the proportions that received Covid-19 vaccine, this would suggest that the estimated effectiveness of the Covid-19 vaccine is unlikely to have been substantially affected by some uncontrolled selection bias.

In this causal diagram, we denote the exposure of interest (Covid-19 vaccine) by the letter "E" and the outcome of interest by the letter "D." Confounding factors are represented by the letter "C," and the letter "S" represents whether a subject is selected to participate in the study. Arrows denote causal pathways between two variables. Conditioning by a particular variable is denoted by a box surrounding the letter, and an "X "over the arrow denotes a disrupted association post-conditioning. The main effect being measured in the matched case-control study (i.e., the vaccine's effectiveness) is emphasized with an Asterix above an arrow. Variable "V" is an exposure that is associated with both immunization status and the unmeasured confounder but is not associated with disease (in effect, a "sham exposure").

Samples collected were nasopharyngeal swabs or nasal swabs in viral transport media. Samples were processed and tested for SARS-Cov-2 as part of routine clinical care at YNHHS-affiliated laboratories that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). For the identification of SARS-CoV-2 RNA, samples were tested using Food and Drug Administration (FDA) authorized assays, which included Xpert Xpress

Aptima SARS-CoV-2 (Hologic) BioGx SARS-CoV-2 Reagents for BD Max

Samples were initially selected for genomic surveillance from confirmed SARS-CoV-2 positive clinical samples obtained for routine testing provided by the Yale Clinical Virology Lab or Yale Pathology lab. We extracted RNA from 300μL of the sample using the MagMax viral/pathogen nucleic acid extraction kit (Thermo Fisher), eluting into 75μL elution buffer. We tested the extracted samples using our "variant of concern" RT-qPCR to determine the SARS-CoV-2 viral load and selected all samples with a cycle threshold <35 for sequencing

Statistical methods for rates and proportions

Power calculations for matched case-control studies

COVID-19 Vaccination Coverage Among Adolescents Aged

Effectiveness of HPV vaccine by age at vaccination and number of doses: protocol for a population-based matched case-control study

Methodological issues in design and analysis of a matched case-control study of a vaccine's effectiveness

Modeling and variable selection in epidemiologic analysis

Step we gaily, on we go

Methods of covariate selection: directed acyclic graphs and the change-in-estimate procedure

Measuring balance and model selection in propensity score methods

Case-control studies of the effectiveness of vaccines: validity and assessment of potential bias

The Pediatric infectious disease journal

Testing in Children in a Large Regional US Health System During the Coronavirus Disease 2019 Pandemic. The Pediatric infectious disease journal

Multiplex qPCR discriminates variants of concern to enhance global surveillance of SARS-CoV-2

RT-qPCR primer-probe sets. Nat Microbiol

An amplicon-based sequencing framework for accurately measuring intrahost virus diversity using PrimalSeq and iVar

Twelve years of SAMtools and BCFtools. Gigascience

Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool

Samples were processed using a multiplexed PCR as previously described. 13 Briefly, samples were prepared in batches of 94 with negative (water) controls incorporated at extraction, cDNA synthesis, and amplicon generation. The Illumina COVIDSeq Test RUO version was used to synthesize cDNA, generate amplicons, and tagment amplicons. Amplicons were pooled and cleaned before quantification with Qubit High-Sensitivity dsDNA kit. The resulting libraries were sequenced using a 2x150 approach on an Illumina NovaSeq at the Yale Center for Genome Analysis, with each sample receiving at least 1 million reads.

Consensus genomes were generated by aligning reads to Wuhan-Hu-1 reference genomes (GenBank MN908937.3) using BWA-MEM v0.7.15. iVar v1.2.1, 14 and SAMTools, 15 were used to trim sequencing adaptors, primer sites, and call bases at >60% frequency at each site with ≥20 reads. An ambiguous "N" was called for sites with fewer than ten reads. Negative controls were confirmed to consist of ≥95% N's in all cases. To assign lineages, samples were analyzed with Pangolin v2.4.2. 16